Published in Cancer Res on May 01, 2008
Principles of cancer therapy: oncogene and non-oncogene addiction. Cell (2009) 10.96
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A (2011) 6.30
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer (2009) 6.28
OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature (2010) 5.73
Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov (2013) 4.72
PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res (2010) 4.50
Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer (2009) 3.90
MYC as a regulator of ribosome biogenesis and protein synthesis. Nat Rev Cancer (2010) 3.64
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR. Nature (2011) 3.18
Clinical implications of the cancer genome. J Clin Oncol (2010) 3.11
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening. Cancer Cell (2011) 2.56
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell (2010) 2.50
Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. J Clin Invest (2010) 2.38
Direct targeting of the mucin 1 oncoprotein blocks survival and tumorigenicity of human breast carcinoma cells. Cancer Res (2009) 2.04
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells. Proc Natl Acad Sci U S A (2011) 2.01
Regulation and function of miRNA-21 in health and disease. RNA Biol (2011) 1.99
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A (2012) 1.91
The molecular pathology of cancer. Nat Rev Clin Oncol (2010) 1.86
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
The role of supercoiling in transcriptional control of MYC and its importance in molecular therapeutics. Nat Rev Cancer (2009) 1.71
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients. Oncotarget (2010) 1.64
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. Neoplasia (2009) 1.64
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov (2014) 1.58
An analogy between the evolution of drug resistance in bacterial communities and malignant tissues. Nat Rev Cancer (2011) 1.58
Survival and death signals can predict tumor response to therapy after oncogene inactivation. Sci Transl Med (2011) 1.56
Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol Oncol (2012) 1.55
The MDM2-p53 pathway revisited. J Biomed Res (2013) 1.52
MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med (2014) 1.51
Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal (2013) 1.45
p21-activated kinase 1: PAK'ed with potential. Oncotarget (2011) 1.44
NCI's provocative questions on cancer: some answers to ignite discussion. Oncotarget (2011) 1.42
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood (2009) 1.42
Heat shock protein Hsp72 controls oncogene-induced senescence pathways in cancer cells. Mol Cell Biol (2008) 1.37
GENT: gene expression database of normal and tumor tissues. Cancer Inform (2011) 1.31
Targeting MYC Expression through G-Quadruplexes. Genes Cancer (2010) 1.29
Expanding roles of ZEB factors in tumorigenesis and tumor progression. Am J Cancer Res (2011) 1.26
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Mol Oncol (2014) 1.26
The MAPK pathway across different malignancies: a new perspective. Cancer (2014) 1.22
NID2 and HOXA9 promoter hypermethylation as biomarkers for prevention and early detection in oral cavity squamous cell carcinoma tissues and saliva. Cancer Prev Res (Phila) (2011) 1.21
Deep sequencing of gastric carcinoma reveals somatic mutations relevant to personalized medicine. J Transl Med (2011) 1.21
Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PLoS One (2011) 1.18
Cancer in light of experimental evolution. Curr Biol (2012) 1.17
Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol (2010) 1.17
Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov (2013) 1.16
Targeted inhibition of the Hedgehog pathway in established malignant glioma xenografts enhances survival. Oncogene (2009) 1.16
Demonstration that drug-targeted down-regulation of MYC in non-Hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J Biol Chem (2011) 1.14
Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition. Mol Cancer (2010) 1.14
Cancer missense mutations alter binding properties of proteins and their interaction networks. PLoS One (2013) 1.14
Regulation and dysregulation of 3'UTR-mediated translational control. Curr Opin Genet Dev (2013) 1.14
Rewiring makes the difference. Mol Syst Biol (2011) 1.13
Outlier kinase expression by RNA sequencing as targets for precision therapy. Cancer Discov (2013) 1.13
Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood (2010) 1.12
Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma. Proc Natl Acad Sci U S A (2012) 1.12
Integration of genomic data enables selective discovery of breast cancer drivers. Cell (2014) 1.11
Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res (2011) 1.10
Pathogenesis of lung cancer signalling pathways: roadmap for therapies. Eur Respir J (2009) 1.10
Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J Biol Chem (2011) 1.10
Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe. Clin Cancer Res (2009) 1.10
Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies. J Cell Mol Med (2012) 1.10
Loss of androgen receptor-dependent growth suppression by prostate cancer cells can occur independently from acquiring oncogenic addiction to androgen receptor signaling. PLoS One (2010) 1.09
Companion diagnostics for targeted cancer drugs - clinical and regulatory aspects. Front Oncol (2014) 1.09
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. J Clin Invest (2013) 1.07
Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J Transl Med (2012) 1.06
Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway. Oncogene (2011) 1.06
Complex oncogene dependence in microRNA-125a-induced myeloproliferative neoplasms. Proc Natl Acad Sci U S A (2012) 1.05
FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma. Clin Exp Metastasis (2012) 1.05
Role of Bcl-3 in solid tumors. Mol Cancer (2011) 1.05
Metabolic reprogramming: the emerging concept and associated therapeutic strategies. J Exp Clin Cancer Res (2015) 1.04
c-Myc induction of programmed cell death may contribute to carcinogenesis: a perspective inspired by several concepts of chemical carcinogenesis. Cancer Biol Ther (2011) 1.04
Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2012) 1.04
Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res (2009) 1.04
Metastasis-associated PRL-3 induces EGFR activation and addiction in cancer cells. J Clin Invest (2013) 1.04
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
FGFR4 blockade exerts distinct antitumorigenic effects in human embryonal versus alveolar rhabdomyosarcoma. Clin Cancer Res (2012) 1.01
Beyond histology: translating tumor genotypes into clinically effective targeted therapies. Clin Cancer Res (2014) 1.01
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol (2015) 1.01
siRNA-based targeting of cyclin E overexpression inhibits breast cancer cell growth and suppresses tumor development in breast cancer mouse model. PLoS One (2010) 1.00
Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Rev Mol Med (2010) 1.00
Taspase1 functions as a non-oncogene addiction protease that coordinates cancer cell proliferation and apoptosis. Cancer Res (2010) 1.00
WRAP53 promotes cancer cell survival and is a potential target for cancer therapy. Cell Death Dis (2011) 1.00
Extracellular signal-regulated kinase positively regulates the oncogenic activity of MCT-1 in diffuse large B-cell lymphoma. Cancer Res (2009) 0.99
AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med (2015) 0.98
Long telomeres bypass the requirement for telomere maintenance in human tumorigenesis. Cell Rep (2012) 0.98
Finding a Panacea among combination cancer therapies. Cancer Res (2011) 0.98
NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128. Oncogenesis (2013) 0.97
BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther (2013) 0.97
Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function. Mol Pharmacol (2010) 0.97
EGFR signaling and autophagy dependence for growth, survival, and therapy resistance. Cell Cycle (2013) 0.97
Immunotherapy targets in pediatric cancer. Front Oncol (2012) 0.97
Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets (2009) 0.96
Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther (2013) 0.96
Evolutionarily conserved protein ERH controls CENP-E mRNA splicing and is required for the survival of KRAS mutant cancer cells. Proc Natl Acad Sci U S A (2012) 0.96
Postal survey of physicians and laboratories: practices and perceptions of molecular oncology testing. BMC Health Serv Res (2009) 0.95